Business Context and Reporting Period
This Form 8-K filing by 22nd Century Group, Inc. covers events occurring on June 30, 2021, with the report dated July 2, 2021. The filing details a material restructuring of the Company's investment and debt relationship with Panacea Life Sciences, Inc. ("PLS") and its affiliate Exactus, Inc. ("Exactus").
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the reporting period. Instead, it outlines specific transaction values related to debt restructuring and asset conversion:
- Debt Restructured: Conversion of an outstanding $7 million principal balance promissory note plus all accrued but unpaid interest.
- Asset Received: Fee simple ownership of Needle Rock Farms (224 acres in Delta County, Colorado) valued at $2.2 million.
- Equity Received: $500,000 in PLS Series B Preferred Stock (subsequently converted to Exactus common stock) and 91,016,026 shares of restricted common stock in Exactus.
- New Debt Instrument: A new $4.3 million promissory note with a maturity date of June 30, 2026, secured by a mortgage on PLS's headquarters in Golden, Colorado.
Material Changes Versus Prior Period
The transaction represents a fundamental change in the Company's exposure to PLS and its affiliates:
- Termination of Prior Rights: All other rights and obligations of the Company in PLS and its affiliate Quintel-MC, Incorporated, were terminated, including all warrant rights and obligations for future investment.
- Debt Conversion: The previous unsecured or differently structured debt obligation was replaced with a mix of real estate assets, equity in Exactus, and a new secured note.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future financial performance. Key contingencies and risks include:
- Security of New Note: The new $4.3 million note is secured by a mortgage on PLS's headquarters; repayment depends on the value and liquidity of this collateral.
- Asset Valuation: The $2.2 million valuation of Needle Rock Farms is an assigned value in the agreement; market liquidity for this real estate asset is not guaranteed.
- Equity Liquidity: The 91+ million shares of Exactus common stock received are restricted, limiting immediate liquidity.
Important Facts for Investor Verification
- Verify the current market value and liquidity of the 91,016,026 shares of Exactus common stock received.
- Confirm the independent appraisal value of Needle Rock Farms to validate the $2.2 million transaction value.
- Review the terms of the new $4.3 million promissory note (interest rate, covenants, and default provisions) once filed in the next Form 10-Q.
- Assess the financial health of Panacea Life Sciences, Inc. and Exactus, Inc. as the primary obligors for the new debt and equity instruments.